This afternoon we watched Insulet drop -8.5% to a price of $182.87 per share. The Large-Cap Medical Instruments & Supplies company is now trading -21.62% below its average target price of $233.32. Analysts have set target prices ranging from $185.0 to $270.0 per share for Insulet, and have given the stock an average rating of buy.
The stock has an average amount of shares sold short at 5.7%, and a short ratio of 4.6. The company's insiders own 0.34% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 102.7% of Insulet's shares being owned by this investor type.
Institutions Invested in Insulet
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-03-31 | Vanguard Group Inc | 12% | 8,199,114 | $1,499,371,937 |
| 2024-03-31 | Capital Research Global Investors | 11% | 7,562,093 | $1,382,879,909 |
| 2024-03-31 | Blackrock Inc. | 9% | 6,025,770 | $1,101,932,530 |
| 2024-03-31 | FMR, LLC | 8% | 5,402,893 | $988,027,016 |
| 2024-03-31 | State Street Corporation | 4% | 2,919,169 | $533,828,420 |
| 2024-03-31 | Wellington Management Group, LLP | 3% | 1,990,242 | $363,955,544 |
| 2024-06-30 | Baillie Gifford and Company | 3% | 1,886,062 | $344,904,148 |
| 2024-03-31 | Citadel Advisors Llc | 2% | 1,668,492 | $305,117,123 |
| 2024-03-31 | Geode Capital Management, LLC | 2% | 1,659,329 | $303,441,486 |
| 2024-03-31 | Morgan Stanley | 2% | 1,388,572 | $253,928,154 |
Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on Insulet.
